CD274 and neoplasm: In keeping with the in vitro observations, a reduced tumor growth rate was observed in both the monoformulated and co-formulated siRNAs, however the co-formulation of siPD-1 and siPD-L1 was shown to be superior with tumor growth comparable to anti PD-L1 mAb [34].